GlassScriptPhysician profile
Jackie Joe Lindo
NPI 1477920296
$1,540.03
in general payments reported to CMS, 2019-2025
23 companies · $241 in 2025
The $241 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $422 · 2022: $171 · 2023: $101 · 2024: $606 · 2025: $241.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $947.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $947.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $215.61 | 2021-2024 | Farxiga, Airsupra |
| Dexcom, INC. | $154.45 | 2021-2024 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $121.87 | 2025 | Recorlev |
| Regeneron Pharmaceuticals, INC. | $116.58 | 2021 | |
| Scynexis, INC. | $112.90 | 2022 | |
| Novo Nordisk INC | $110.71 | 2023-2024 | Wegovy |
| Glaxosmithkline, LLC. | $98.46 | 2024-2025 | Nucala, Fluarix Quadrivalent, Trelegy Ellipta |
| Abbvie INC. | $82.56 | 2024-2025 | |
| Amgen INC. | $70.69 | 2024 | Repatha, Otezla |
| Qiagen, LLC | $64.27 | 2023 | |
| Lilly USA, LLC | $61.10 | 2024 | Zepbound, Mounjaro, Jardiance |
| Genentech USA, INC. | $45.42 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.92 | 2024-2025 | Jardiance |
| Corcept Therapeutics | $42.70 | 2024 | Korlym |
| Biohaven Pharmaceuticals, INC. | $30.68 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $29.61 | 2024 | |
| Phathom Pharmaceuticals, INC. | $27.95 | 2024-2025 | Voquezna |
| Abbott Laboratories | $22.81 | 2024 | Freestyle Libre 3 |
| Astellas Pharma US INC | $20.93 | 2024 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $20.27 | 2024 | |
| Merck Sharp & Dohme LLC | $17.29 | 2024 | Capvaxive, Gardasil 9, Gardasil |
| Otsuka America Pharmaceutical, INC. | $16.86 | 2024 | Rexulti |
| Evofem Biosciences, INC. | $12.39 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jackie Joe Lindo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.